Perspectives for the treatment of infections with Flaviviridae

Clinical Microbiology Reviews

Volumn 13, Issue 1, 2000, Pages 67-82

  Leyssen, Pieter ^a   De Clercq, Erik ^a   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYL 4 IMIDAZOLECARBOXAMIDE 1 RIBOSIDE; CARBAZOCHROME; CORTICOSTEROID; DEXAMETHASONE; FOMIVIRSEN; HELICASE INHIBITOR; HYDROCORTISONE SODIUM SUCCINATE; LYMPHOBLAST INTERFERON; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PROTEINASE INHIBITOR; REBETRON; RECOMBINANT ALPHA1N INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT METINTERFERON CON1; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; SELENAZOFURIN; TIAZOFURIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DOG; FLAVIVIRUS; GENE THERAPY; HEMOLYTIC ANEMIA; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIVER CIRRHOSIS; MONKEY; MOUSE; NONHUMAN; PESTIVIRUS; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ACARI; ANIMALIA; ARTHROPODA; CANIS FAMILIARIS; FLAVIVIRIDAE; FLAVIVIRUS; HEPACIVIRUS; HEPATITIS C VIRUS; JAPANESE ENCEPHALITIS VIRUS; PESTIVIRUS; RNA VIRUSES; YELLOW FEVER VIRUS GROUP;

EID: 0033982257     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.13.1.67-82.2000     Document Type: Article

References (263)

1. Al, R. H., Y. Xie, Y. Wang, and C. H. Hagedorn. 1998. Expression of recombinant hepatitis C virus non-structural protein 5B in Escherichia coli. Virus Res. 53:141-149.
2. Alt, M., R. Renz, P. H. Hofschneider, and W. H. Caselmann. 1997. Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation. Arch. Virol. 142:589-599.
3. Alter, M. J., E. E. Mast, L. A. Moyer, and H. S. Margolis. 1998. Hepatitis C. Infect. Dis. Clin. North Am. 12:13-26.
4. Andries, K., B. Dewindt, J. Snoeks, R. Willebrords, K. van Eemeren, R. Stokbroekx, and P. A. Janssen. 1992. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob. Agents Chemother. 36:100-107.
5. Angsubhakorn, S., J. B. Moe, N. J. Marchette, J. R. Latendresse, N. E. Palumbo, S. Yoksan, and N. Bhamarapravati. 1987. Neurovirulence detection of dengue virus using rhesus and cynomolgus monkeys. J. Virol. Methods 18:13-24.
6. Arroyo, J. I., S. A. Apperson, C. B. Cropp, B. J. Marafino, Jr., T. P. Monath, R. B. Tesh, R. E. Shope, and M. A. Garcia Blanco. 1988. Effect of human gamma interferon on yellow fever virus infection. Am. J. Trop. Med. Hyg. 38:647-650.
7. Askari, F. K., and W. M. McDonnell. 1996. Antisense-oligonucleotide therapy. N. Engl. J. Med. 334:316-318.
8. Baker, J. C. 1987. Bovine viral diarrhea virus: a review. J. Am. Vet. Med. Assoc. 190:1449-1458.
9. Balzarini, J., A. Karlsson, L. Wang, C. Bohman, K. Horska, I. Votruba, A. Fridland, A. Van Aerschot, P. Herdewijn, and E. De Clercq. 1993. Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. J. Biol. Chem. 268:24591-24598.
10. Balzarini, J., J. Neyts, D. Schols, M. Hosoya, E. Van Damme, W. Peumans, and E. De Clercq. 1992. The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro. Antiviral Res. 18:191-207.
11. Balzarini, J., D. Schols, J. Neyts, A. Van Aerschot, W. Peumans, and E. De Clercq. 1991. Alpha-(1-3)-and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. Antimicrob. Agents Chemother. 35:410-416.
12. Bartenschlager, R. 1997. Molecular targets in inhibition of hepatitis C virus replication. Antiviral Chem. Chemother. 8:281-301.
13. Bartholomeusz, A., E. Tomlinson, P. J. Wright, C. Birch, S. Locarnini, H. Weigold, S. Marcuccio, and G. Holan. 1994. Use of a flavivirus RNA-dependent RNA polymerase assay to investigate the antiviral activity of selected compounds. Antiviral Res. 24:341-350.
14. Bartholomeusz, A. I., and P. J. Wright. 1993. Synthesis of dengue virus RNA in vitro: initiation and the involvement of proteins NS3 and NS5. Arch. Virol. 128:111-121.
15. Bassett, S. E., K. M. Brasky, and R. E. Lanford. 1998. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. J. Virol. 72:2589-2599.
16. Becher, P., G. Meyers, A. D. Shannon, and H. J. Thiel. 1996. Cytopathogenicity of border disease virus is correlated with integration of cellular sequences into the viral genome. J. Virol. 70:2992-2998.
17. Behrens, S. E., C. W. Grassmann, H. J. Thiel, G. Meyers, and N. Tautz. 1998. Characterization of an autonomous subgenomic pestivirus RNA replicon. J. Virol. 72:2364-2372.
18. Behrens, S. E., L. Tomei, and R. De Francesco. 1996. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15:12-22.
19. Benvegnu, L., L. Chemello, F. Noventa, G. Fattovich, P. Pontisso, and A. Alberti. 1998. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 83:901-909.
20. Bianchi, E., C. Steinkuhler, M. Taliani, A. Urbani, R. D. Francesco, and A. Pessi. 1996. Synthetic depsipeptide substrates for the assay of human hepatitis C virus protease. Anal. Biochem. 237:239-244.
21. Bielefeldt-Ohmann, H. 1997. Pathogenesis of dengue virus diseases: missing pieces in the jigsaw. Trends Microbiol. 5:409-413.
22. Bolin, S. R. 1995. Control of bovine viral diarrhea infection by use of vaccination. Vet. Clin. North Am. Food Anim. Pract. 11:615-625.
23. Bonn, D. 1996. Prospects for antisense therapy are looking brighter. Lancet 347:820.
24. Bray, M., R. Men, I. Tokimatsu, and C. J. Lai. 1998. Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence. J. Virol. 72:1647-1651.
25. Bruschke, C. J., M. M. Hulst, R. J. Moormann, P. A. Van Rijn, and J. T. Van Oirschot. 1997. Glycoprotein Erns of pestiviruses induces apoptosis in lymphocytes of several species. J. Virol. 71:6692-6696.
26. Bruschke, C. J., K. Weerdmeester, J. T. Van Oirschot, and P. A. Van Rijn. 1998. Distribution of bovine virus diarrhoea virus in tissues and white blood cells of cattle during acute infection. Vet. Microbiol. 64:23-32.
27. Bukh, J., C. L. Apgar, R. Engle, S. Govindarajan, P. A. Hegerich, R. Tellier, D. C. Wong, R. Elkins, and M. C. Kew. 1998. Experimental infection of chimpanzees with hepatitis C virus of genotype 5a: genetic analysis of the virus and generation of a standardized challenge pool. J. Infect. Dis. 178: 1193-1197.
28. Bukh, J., J. P. Kim, S. Govindarajan, C. L. Apgar, S. K. Foung, J. Wages, A. J. Yun, M. Shapiro, S. U. Emerson, and R. H. Purcell. 1998. Experimental infection of chimpanzees with hepatitis G virus and genetic analysis of the virus. J. Infect. Dis. 177:855-862.
29. Cacopardo, B., F. Benanti, G. Brancati, F. Romano, and A. Nunnari. 1998. Leucocyte interferon-alpha retreatment for chronic hepatitis C patients previously intolerant to other interferons. J. Viral Hepat. 5:333-339.
30. Caffrey, J. F., A. M. Dudgeon, W. J. Donnelly, B. J. Sheahan, and G. J. Atkins. 1997. Morphometric analysis of growth retardation in fetal lambs following experimental infection of pregnant ewes with border disease virus. Res. Vet. Sci. 62:245-248.
31. Cai, W., E. Maier, N. Morin, E. Ilan, J. Schwedesl, P. Cai, K. Hubermanl, S. Dagan, R. Rondo, A. Heguy, and S. Mounir. 1998. Discovery of anti-HCV IRES compound, general session I, presentation 5. In Symposium on Emerging Therapies for Chronic Viral Hepatitis.
32. Canonico, P. G., M. Kende, B. J. Luscri, and J. W. Huggins. 1984. In-vivo activity of antivirals against exotic RNA viral infections. J. Antimicrob. Chemother. 14(Suppl. A):27-41.
33. Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice. 1990. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44:649-688.
34. Chen, Y., T. Maguire, R. E. Hileman, J. R. Fromm, J. D. Esko, R. J. Linhardt, and R. M. Marks. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3:866-871.
35. Chen, Y., T. Maguire, and R. M. Marks. 1996. Demonstration of binding of dengue virus envelope protein to target cells. J. Virol. 70:8765-8772.
36. Cho, Y. G., S. H. Yang, and Y. C. Sung. 1998. In vivo assay for hepatitis C viral serine protease activity using a secreted protein. J. Virol. Methods 72:109-115.
37. Chon, S. K., D. R. Perez, and R. O. Donis. 1998. Genetic analysis of the internal ribosome entry segment of bovine viral diarrhea virus. Virology 251:370-382.
38. Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
39. Clarysse, C., J. Neyts, E. De Clercq, N. Ammack, and S. H. Yap. 1998. Sulfated polymers but not ribavirin or interferon inhibit the infection of immortalized human hepatocytes by HCV. In Congress of the American Association for the Study of Liver Diseases and the International Association for the Study of the Liver.
40. Cortese, V. S., D. L. Grooms, J. Ellis, S. R. Bolin, J. F. Ridpath, and K. V. Brock. 1998. Protection of pregnant cattle and their fetuses against infection with bovine viral diarrhea virus type 1 by use of a modified-live virus vaccine. Am. J. Vet. Res. 59:1409-1413.
41. Cortese, V. S., R. Whittaker, J. Ellis, J. F. Ridpath, and S. R. Bolin. 1998. Specificity and duration of neutralizing antibodies induced in healthy cattle after administration of a modified-live virus vaccine against bovine viral diarrhea. Am. J. Vet. Res. 59:848-850.
42. Dagan, S., O. Nussbaum, R. Eren, O. Ben-Moshe, Y. Arazi, S. Berre, I. Lubin, D. Shouval, E. Galun, Y. Reisner, and E. Ilan. 1998. The trimera pouse: an HBV and HCV infection model for evaluation of antiviral therapeutic agents, general session II, presentation 3. In Symposium on Emerging Therapies for Chronic Viral Hepatitis.
43. Davidson, M. M., H. Williams, and J. A. Macleod. 1991. Louping ill in man: a forgotten disease. J. Infect. 23:241-249.
44. Davis, G. L. 1998. Anticipated mortality of hepatitis C and impact of treatment. Hepatology 28:390A.
45. Davis, G. L. 1999. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Semin. Liver Dis. 19(Suppl. 1):49-55.
46. Davis, G. L., L. A. Balart, E. R. Schiff, K. Lindsay, H. C. Bodenheimer, Jr., R. P. Perrillo, W. Carey, I. M. Jacobson, J. Payne, J. L. Dienstag, et al. 1990. Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group. J. Hepatol. 11(Suppl. 1):S31-S35.
47. Davis, G. L., R. Esteban Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. Shiffman, S. Zeuzem, A. Craxi, M. H. Ling, and J. Albrecht. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1493-1499.
48. Davis, J. W., and J. L. Hardy. 1973. In vitro studies with Modoc virus in Vero cells: plaque assay and kinetics of growth, neutralization, and thermal inactivation. Appl. Microbiol. 26:344-348.
49. Davis, J. W., J. L. Hardy, and W. C. Reeves. 1974. Modoc viral infections in the deer mouse Peromyscus maniculatus. Infect. Immun. 10:1362-1369.
50. De Clercq, E. 1993. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv. Virus Res. 42:1-55.
51. De Clercq, E., M. Cools, J. Balzarini, R. Snoeck, G. Andrei, M. Hosoya, S. Shigeta, T. Ueda, N. Minakawa, and A. Matsuda. 1991. Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob. Agents Chemother. 35:679-684.
52. Deeks, S. G., M. Smith, M. Holodniy, and J. O. Kahn. 1997. HIV-1 protease inhibitors. A review for clinicians. JAMA 277:145-153.
53. Dimasi, N., F. Martin, C. Volpari, M. Brunetti, G. Biasiol, S. Altamura, R. Cortese, R. De Francesco, C. Steinkuhler, and M. Sollazzo. 1997. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires. J. Virol. 71:7461-7469.
54. Donis, R. O., and E. J. Dubovi. 1987. Differences in virus-induced polypeptides in cells infected by cytopathic and noncytopathic biotypes of bovine virus diarrhea-mucosal disease virus. Virology 158:168-173.
55. Donzella, G. A., D. Schols, S. W. Lin, J. A. Este, K. A. Nagashima, P. J. Maddon, G. P. Allaway, T. P. Sakmar, G. Henson, E. De Clercq, and J. P. Moore. 1998. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4:72-77.
56. Dutta, U., J. Kench, K. Byth, M. H. Khan, R. Lin, C. Liddle, and G. C. Farrell. 1998. Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C. Hum. Pathol. 29:1279-1284.
57. Edwards, S., P. M. Roehe, and G. Ibata. 1995. Comparative studies of border disease and closely related virus infections in experimental pigs and sheep. Br. Vet. J. 151:181-187.
58. Ellis, J. A., K. H. West, V. S. Cortese, S. L. Myers, S. Carman, K. M. Martin, and D. M. Haines. 1998. Lesions and distribution of viral antigen following an experimental infection of young seronegative calves with virulent bovine virus diarrhea virus-type II. Can. J. Vet. Res. 62:161-169.
59. Fabris, P., M. R. Biasin, D. Infantolino, L. Romano, P. Benedetti, G. Tositti, G. P. Pellizzer, A. R. Zanetti, C. Stecca, G. Marchelle, and F. de Lalla. 1998. HGV/GBV-C in liver tissue and in sera from patients with chronic hepatitis C. Infection 26:283-287.
60. Fabris, P., D. Infantolino, M. R. Biasin, P. Benedetti, G. Tositti, C. Bettini, G. Marchelle, and F. de Lalla. 1998. HGV/GBV-C infection in patients with acute hepatitis of different etiology and in patients with chronic hepatitis C. J. Gastroenterol. 33:57-61.
61. Failla, C., L. Tomei, and R. De Francesco. 1994. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J. Virol. 68:3753-3760.
62. Filocamo, G., L. Pacini, C. Nardi, L. Bartholomew, M. Scaturro, P. Delmastro, A. Tramontano, R. De Francesco, and G. Migliaccio. 1999. Selection of functional variants of the NS3-NS4A protease of hepatitis C virus by using chimeric Sindbis viruses. J. Virol. 73:561-575.
63. Flexner, C. 1998. HIV-protease inhibitors. N. Engl. J. Med. 338:1281-1292.
64. Flores-Aguilar, M., G. Besen, C. Vuong, M. Tatebayashi, D. Munguia, P. Gangan, C. A. Wiley, and W. R. Freeman. 1997. Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. J. Infect. Dis. 175:1308-1316.
65. Fournier, C., C. Sureau, J. Coste, J. Ducos, G. Pageaux, D. Larrey, J. Domergue, and P. Maurel. 1998. In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus. I. Gen. Virol. 79:2367-2374.
66. Fujiwara, K., S. Mochida, S. Matsuo, I. Ogata, S. Hayashi, and Y. Sato. 1998. Randomized control trial of interferon-beta injections at 12-h intervals as a therapy for chronic hepatitis C. Hepatol. Res. 12:240-251.
67. Gabrielsen, B., M. J. Phelan, L. Barthel Rosa, C. See, J. W. Huggins, D. F. Kefauver, T. P. Monath, M. A. Ussery, G. N. Chmurny, and E. M. Schubert et al. 1992. Synthesis and antiviral evaluation of N-carboxamidine-substituted analogues of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride. J. Med. Chem. 35:3231-3238.
68. Gale, M., C. M. Blakely, B. Kwieciszewski, S. L. Tan, M. Dossett, N. M. Tang, M. J. Korth, S. J. Polyak, D. R. Gretch, and M. G. Katze. 1998. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell. Biol. 18:5208-5218.
69. Gallinari, P., D. Brennan, C. Nardi, M. Brunetti, L. Tomei, C. Steinkuhler, and R. De Francesco. 1998. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J. Virol. 72:6758-6769.
70. Ghosh, S. N., M. K. Goverdhan, P. S. Sathe, S. C. Chelliah, S. V. Naik, P. V. Godbole, and K. Banerjee. 1990. Protective effect of 6-MFA, a fungal interferon inducer against Japanese encephalitis virus in bonnet macaques. Indian J. Med. Res. 91:408-413.
71. Gilbert, B. E., S. Z. Wilson, V. Knight, R. B. Couch, J. M. Querles, L. Dure, N. Hayes, and G. Willis. 1985. Rihavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob. Agents Chemother. 27:309-313.
72. Gish, R. G. 1999. Standards of treatment in chronic hepatitis C. Semin. Liver. Dis. 19(Suppl. 1):35-47.
73. Gonzalez-Peralta, R. P., G. J. Galasso, T. Poynard, S. Schalm, H. C. Thomas, and T. L. Wright. 1999. Summary of the first international symposium on viral hepatitis. Antiviral Res. 42:77-96.
74. Goswami, B. B., E. Borek, O. K. Sharma, J. Fujitaki, and R. A. Smith. 1979. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 89:830-836.
75. Goverdhan, M. K., A. B. Kulkarni, A. K. Gupta, C. D. Tupe, and J. J. Rodrigues. 1992. Two-way cross-protection between West Nile and Japanese encephalitis viruses in bonnet macaques. Acta Virol. 36:277-283.
76. Grimaldi, S., A. Lisi, D. Pozzi, and N. Santoro. 1997. Attempts to use liposomes and RBC ghosts as vectors in drug and antisense therapy of virus infection. Res. Virol. 148:177-180.
77. Gubler, D. J. 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11:480-496.
78. Gupta, R. K., C. N. Misra, V. K. Gupta, and S. N. Saxena. 1991. An efficient method for production of purified inactivated Japanese encephalitis vaccine from mouse brains. Vaccine 9:865-867.
79. Hahm, B., S. H. Back, T. G. Lee, E. Wimmer, and S. K. Jang. 1996. Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity. Virology 226:318-326.
80. Han, J. H., V. Shyamala, K. H. Richman, M. J. Brauer, B. Irvine, M. S. Urdea, O. P. Tekamp, G. Kuo, Q. L. Choo, and M. Houghton. 1991. Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5′ untranslated region and poly(A) tails at the 3′ end. Proc. Natl. Acad. Sci. USA 88:1711-1715.
81. Han, L. L., F. Popovici, J. P. Alexander, V. Laurentia, L. A. Tengelsen, C. Cernescu, H. E. Gary, N. Ion Nedelcu, G. L. Campbell, and T. F. Tsai. 1999. Risk factors for West Nile virus infection and meningoencephalitis. Romania, 1996. J. Infect. Dis. 179:230-233.
82. Harinasuta, C., S. Nimmanitya, and U. Titsyakorn. 1985. The effect of interferon-alpha A on two cases of Japanese encephalitis in Thailand. Southeast Asian J. Trop. Med. Public Health 16:332-336.
83. Hayden, F. G., G. J. Hipskind, D. H. Woerner, G. F. Eisen, M. Janssens, P. A. Janssen, and K. Andries. 1995. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob. Agents Chemother. 39:290-294.
84. Heathcote, J. 1998. Consensus interferon: a novel interferon for the treatment of hepatitis C. J. Viral Hepat. 5(Suppl. 1):13-18.
85. Heinz, F. X., and C. W. Mandl. 1993. The molecular biology of tick-borne encephalitis virus. APMIS 101:735-745.
86. Hewicker, T. M., B. Liess, and G. Trautwein. 1995. Brain lesions in calves following transplacental infection with bovine-virus diarrhoea virus. Zentralbl. Veterinarmed. Reihe B 42:65-77.
87. Higgs, S., and E. A. Gould. 1991. Differences in fusogenicity and mouse neurovirulence of Japanese encephalitis viruses. Arch. Virol. 119:119-133.
88. Hoke, C. H., Jr., D. W. Vaughn, A. Nisalak, P. Intralawan, S. Poolsuppasit, V. Jongsawas, U. Titsyakorn, and R. T. Johnson. 1992. Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus. J. Infect. Dis. 165:631-637.
89. Holzmann, H., F. X. Heinz, C. W. Mandl, F. Guirakhoo, and C. Kunz. 1990. A single amino acid substitution in envelope protein E of tick-borne encephalitis virus leads to attenuation in the mouse model. J. Virol. 64:5156-5159.
90. Hoofnagle, J. H. 1997. Hepatitis C: the clinical spectrum of disease. Hepatology 26:15S-20S.
91. Hoofnagle, J. H., D. Lau, H. Conjeevaram, D. Kleiner, and A. M. Di Bisceglie. 1996. Prolonged therapy of chronic hepatitis C with ribavirin. J. Viral Hepat. 3:247-252.
92. Houe, H. 1999. Epidemiological features and economical importance of bovine virus diarrhoea virus (BVDV) infections. Vet. Microbiol. 64:89-107.
93. Houghton, M. 1996. Hepatitis C viruses, p. 1035-1058. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 1. Lippincott-Raven Publishers, Philadelphia, Pa.
94. Huggins, J. W. 1989. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis. 11(Suppl. 4):S750-S761.
95. Huggins, J. W., G. R. Kim, O. M. Brand, and K. T. McKee, Jr. 1986. Ribavirin therapy for Hantaan virus infection in suckling mice. J. Infect. Dis. 153:489-497.
96. Huggins, J. W., R. K. Robins, and P. G. Canonico. 1984. Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses. Antimicrob. Agents Chemother. 26:476-480.
97. Huggins, J. W., Z. X. Zhang, and M. Bray. 1999. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J. Infect. Dis. 179(Suppl. 1):S240-S247.
98. Hultgren, C., D. R. Milich, O. Weiland, and M. Sallberg. 1998. The antiviral compound ribavirin modulates the T helper (Th) 1ATh2 subset balance in hepatitis B and C virus-specific immune responses. J. Gen. Virol. 79:2381-2391.
99. Ikeda, M., K. Sugiyama, T. Mizutani, T. Tanaka, K. Tanaka, K. Shimotohno, and N. Kato. 1997. Hepatitis G virus replication in human cultured cells displaying susceptibility to hepatitis C virus infection. Biochem. Biophys. Res. Commun. 235:505-508.
100. Ikeda, S., J. Neyts, S. Verma, A. Wickramasinghe, P. Mohan, and E. De Clercq. 1994. In vitro and in vivo inhibition of ortho-and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion. Antimicrob. Agents Chemother. 38:256-259.
101. Ingallinella, P., S. Altamura, E. Bianchi, M. Taliani, R. Ingenito, R. Cortese, R. De Francesco, C. Steinkuhler, and A. Pessi. 1998. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry 37:8906-8914.
102. Ito, T., S. M. Tahara, and M. M. Lai. 1998. The 3′-untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site. J. Virol. 72:8789-8796.
103. Johnson, A. J., and J. T. Roehrig. 1999. New mouse model for dengue virus vaccine testing. J. Virol. 73:783-786.
104. Kakiuchi, N., Y. Komoda, K. Komoda, N. Takeshita, S. Okada, T. Tani, and K. Shimotohno. 1998. Non-peptide inhibitors of HCV serine proteinase. FEBS Lett. 421:217-220.
105. Kalita, J., and U. K. Misra. 1998. EEG in Japanese encephalitis: a clinicoradiological correlation. Electroenccphalogr. Clin. Neurophysiol. 106:238-243.
106. Kaluzova, M., E. Eleckova, E. Zuffova, J. Pastorek, S. Kaluz, O. Kozuch, and M. Labuda. 1994. Reverted virulence of attenuated tick-borne encephalitis virus mutant is nol accompanied with the changes in deduced viral envelope protein amino acid sequence. Acta Virol. 38:133-140.
107. Kanai, K., M. Kako, T. Kumada, H. Tsubouchi, T. Aikawa, M. Kojima, H. Harada, T. Kawasaki, M. Nakashima, H. Okamoto, and S. Mishiro. 1998. High-dose (9 MU) long-term (60 weeks) alfa-interferon therapy for chronic hepatitis patients infected with HCV genotype 1b. Arch. Virol. 143:1545-1554.
108. Karayiannis, P., J. Pickering, R. Zampino, and H. C. Thomas. 1998. Natural history and molecular biology of hepatitis G virus GB virus C. Clin. Diagn. Virol. 10:103-111.
109. Kasai, Y., S. Takeda, and H. Takagi, 1996. Pathogenesis of hepatocellular carcinoma: a review from the viewpoint of molecular analysis. Semin. Surg. Oncol. 12:155-159.
110. Kawano, H., V. Rostapshov, L. Rosen, and C. J. Lai. 1993. Genetic determinants of dengue type 4 virus neurovirulence for mice. J. Virol. 67:6567-6575.
111. Kern, B., K. R. Depner, W. Letz, M. Rott, S. Thalheim, B. Nitschke, R. Plagemann, and B. Liess. 1999. Incidence of classical swine fever (CSF) in wild boar in a densely populated area indicating CSF virus persistence as a mechanism for virus perpetuation. Zentralbl. Veterinarmed. Reihe B 46: 63-67.
112. Khettry, U., C. Robiou, R. L. Jenkins, M. Loda, and W. D. Lewis. 1998. Recurrent hepatitis C in liver allografts: early histologic indicators. Int. J. Surg. Pathol. 6:197-204.
113. Kim, D. W., Y. Gwack, J. H. Han, and J. Choe. 1997. Towards defining a minimal functional domain for NTPase and RNA helicase activities of the hepatitis C virus NS3 protein. Virus Res. 49:17-25.
114. Kim, D. W., J. Kim, Y. Gwack, J. H. Han, and J. Choe. 1997. Mutational analysis of the hepatitis C virus RNA helicase. J. Virol. 71:9400-9409.
115. Kim, J. L., and P. R. Caron. 1998. Crystal structure of hepatitis C NS3 RNA helicase reveals a possible enzyme mechanism and suggests multiple drug binding sites. Int. Antiviral News 6:25-28.
116. Kim, J. L., K. A. Morgenstern, J. P. Griffith, M. D. Dwyer, J. A. Thomson, M. A. Murcko, C. Lin, and P. R. Caron. 1998. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 6:89-100.
117. Kim, J. L., K. A. Morgenstern, C. Lin, T. Fox, M. D. Dwyer, J. A. Landro, S. P. Chambers, W. Markland, C. A. Lepre, E. T. O'Malley, S. L. Harbeson, C. M. Rice, M. A. Murcko, P. R. Caron, and J. A. Thomson. 1996. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343-355. (Erratum 89:159, 1997.)
118. Kleter, B., J. T. Brouwer, F. Nevens, L. J. van Doorn, A. Elewaut, J. Versieck, P. P. Michielsen, M. L. Hautekeete, R. A. Chamuleau, R. Brenard, N. Bourgeois, M. Adler, W. G. Quint, C. M. Bronkhorst, R. A. Heijtink, W. J. Hop, J. Fevery, and K. W. Schalm. 1998. Hepatitis C virus genotypes: epidemiological and clinical associations. Benelux Study Group on Treatment of Chronic Hepatitis C Liver 18:32-38.
119. Koff, W. C., R. D. Pratt, J. L. Elm, Jr., C. N. Venkateshan, and S. B. Halstead. 1983. Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin. Antimicrob. Agents Chemother. 24:134-136.
120. Kolykhalov, A. A., S. M. Feinstone, and C. M. Rice. 1996. Identification of a highly conserved sequence element at the 3′ terminus of hepatitis C virus genome RNA. J. Virol. 70:3363-3371.
121. Koonin, E. V. 1993. Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus. J. Gen. Virol. 74:733-740.
122. Kosmidou, A., M. Buttner, and G. Meyers. 1998. Isolation and characterization of cytopathogenic classical swine fever virus (CSFV). Arch. Virol. 143:1295-1309.
123. Kramer, L. D., S. B. Presser, J. L. Hardy, and A. O. Jackson. 1997. Genotypic and phenotypic variation of selected Saint Louis encephalitis viral strains isolated in California. Am. J. Trop. Med. Hyg. 57:222-229.
124. Kummerer, B. M., D. Stoll, and G. Meyers. 1998. Bovine viral diarrhea virus strain Oregon: a novel mechanism for processing of NS2-3 based on point mutations. J. Virol. 72:4127-4138.
125. Kuno, G., G. J. Chang, K. R. Tsuchiya, N. Karabatsos, and C. B. Cropp. 1998. Phylogeny of the genus Flavivirus. J. Virol. 72:73-83.
126. Kurane, I., A. L. Rothman, P. G. Livingston, S. Green, S. J. Gagnon, J. Janus, B. L. Innis, S. Nimmannitya, A. Nisalak, and F. A. Ennis. 1994. Immunopathologic mechanisms of dengue hemorrhagic fever and dengue shock syndrome. Arch. Virol. Suppl. 9:59-64.
127. Laevens, H., H. Deluyker, F. Koenen, G. Van Caenegem, J. P. Vermeersch, and A. de Kruif. 1998. An experimental infection with a classical swine fever virus in weaner pigs. II. The use of serological data to estimate the day of virus introduction in natural outbreaks. Vet. Q. 20:46-49.
128. Reference deleted.
129. Laevens, H., F. Koenen, H. Deluyker, D. Berkvens, and A. de Kruif. 1998. An experimental infection with a classical swine fever virus in weaner pigs. I. Transmission of the virus, course of the disease, and antibody response. Vet. Q. 20:41-45.
130. Lamarre, D. 1998. Biological characterization and pcptide-based inhibition of the hepatitis C virus NS3 serine protease, general session I, presentation 7. Symposium on Emerging Therapies for Chronic Viral Hepatitis.
131. Lau, D. Y., D. E. Kleiner, M. G. Ghany, Y. Park, P. Schmid, and J. H. Hoofnagle. 1998. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 28:1121-1127.
132. Lau, J. Y., K. Qian, J. Detmer, M. L. Collins, E. Orito, J. A. Kolberg, M. S. Urdea, M. Mizokami, and G. L. Davis. 1997. Effect of interferon-alpha and ribavirin therapy on serum GB virus C/hepatitis G virus (GBV-C/HGV) RNA levels in patients chronically infected with hepatitis C virus and GBV-C/HGV. J. Infect. Dis. 176:421-426.
133. Lavanchy, D., R. Purcell, F. B. Hollinger, C. Howard, A. Alberti, M. Kew, G. Dusheiko, M. Alter, E. Ayoola, P. Beutels, R. Bloomer, B. Ferret, R. Decker, R. Esteban, O. Fay, H. Fields, E. C. Fuller, P. Grob, M. Houghton, N. Leung, S. A. Locarnini, H. Margolis, A. Meheus, T. Miyamura, M. K. Mohamed, B. Tandon, D. Thomas, H. T. Head, A. U. Toukan, P. Van Damme, A. Zanetti, R. Arthur, M. Couper, R. D'Amelio, J. C. Emmanuel, K. Esteves, P. Gavinio, E. Griffiths, Z. Hallaj, C. C. Heuck, D. L. Heymann, S. E. Holck, M. Kane, L. J. Martinez, F. Meslin, I. S. Mochny, A. Ndikuyeze, A. M. Padilla, G. M. Rodier, C. Roure, F. Savage, and G. Vercauteren. 1999. Global surveillance and control of hepatitis C. J. Viral Hepat. 6:35-47.
134. Laxton, C. D., D. McMillan, V. Sullivan, and A. M. Ackrill. 1998. Expression and characterization of the hepatitis G virus helicase. J. Viral Hepat. 5:21-26.
135. Le, S. Y., W. M. Liu, and J. V. Maizel, Jr. 1998. Phylogenetic evidence for the improved RNA higher-order structure in internal ribosome entry sequences of HCV and pestiviruses. Virus Genes 17:279-295.
136. Lee, J. H., M. von Wagner, W. K. Roth, G. Teuber, C. Sarrazin, and S. Zeuzem. 1998. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. J. Hepatol. 29:29-35.
137. Levenbook, I. S., L. J. Pelleu, and B. L. Elisberg. 1987. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. J. Biol. Stand. 15:305-313.
138. Lieber, A., C. Y. He, S. J. Polyak, D. R. Gretch, D. Barr, and M. A. Kay. 1996. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J. Virol. 70:8782-8791.
139. Lieber, A., and M. A. Kay. 1996. Adenovirus-mediated expression of ribozymes in mice. J. Virol. 70:3153-3158.
140. Liebler Tenorio, E. M., W. I. Greiser, and J. F. Pohlenz. 1997. Organ and tissue distribution of the antigen of the cytopathogenic bovine virus diarrhea virus in the early and advanced phase of experimental mucosal disease. Arch. Virol. 142:1613-1634.
141. Liebler Tenorio, E. M., and J. F. Pohlenz. 1997. Experimental mucosal disease of cattle: changes in cell proliferation in lymphoid tissues and intestinal epithelium. J. Comp. Pathol. 117:339-350.
142. Lin, Y. L., C. L. Liao, L. K. Chen, C. T. Yeh, C. I. Liu, S. H. Ma, Y. Y. Huang, Y. L. Huang, C. L. Kao, and C. C. King. 1998. Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J. Virol. 72:9729-9737.
143. Lindberg, A. E., and S. Alenius. 1999. Principles for eradication of bovine viral diarrhoea virus (BVDV) infections in cattle populations. Vet. Microbiol. 64:197-222.
144. Lindenbach, B. D., and C. M. Rice. 1997. trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication. J. Virol. 71:9608-9617.
145. Linnen, J., J. Wages, Z. Y. Zhang Keck, K. E. Fry, K. Z. Krawczynski, H. Alter, E. Koonin, M. Gallagher, M. Alter, S. Hadziyannis, P. Karayiannis, K. Fung, Y. Nakatsuji, J. W. Shih, L. Young, M. Piatak, C. Hoover, J. Fernandez, S. Chen, J. C. Zou, T. Morris, K. C. Hyams, S. Ismay, J. D. Lifson, J. P. Kim, et al. 1996. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 271:505-508.
146. Liu, C. T., and M. J. Griffin. 1982. Changes in body fluid compartments, tissue water and electrolyte distribution, and lipid concentrations in rhesus macaques with yellow fever. Am. J. Vet. Res. 43:2013-2018.
147. Lohmann, V., F. Korner, U. Herian, and R. Bartenschlager. 1997. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J. Virol. 71:8416-8428.
148. Lohmann, V., F. Korner, J. Koch, U. Herian, L.Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
149. Lopez Labrador, F. X., S. Ampurdanes, M. Gimenez Barcons, M. Guilera, J. Costa, M. T. J. de Anta, J. M. Sanchez Tapias, J. Rodes, and J. C. Saiz. 1999. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b interferon. Hepatology 29:897-903.
150. Lu, H. H., and E. Wimmer. 1996. Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus. Proc. Natl. Acad. Sci. USA 93:1412-1417.
151. Lum, L. C., S. K. Lam, Y. S. Choy, R. George, and F. Harun. 1996. Dengue encephalitis: a true entity? Am. J. Trop. Med. Hyg. 54:256-259.
152. Mackenzie, J. M., A. A. Khromykh, M. K. Jones, and E. G. Westaway. 1998. Subcellular localization and some biochemical properties of the flavivirus Kunjin nonstructural proteins NS2A and NS4A. Virology 245:203-215.
153. Mackenzie, J. S., and A. K. Broom. 1995. Australian X disease, Murray Valley encephalitis and the French connection. Vet. Microbiol. 46:79-90.
154. Mady, B. J., I. Kurane, D. V. Erbe, M. W. Fanger, and F. A. Ennis. 1993. Neuraminidase augments Fc gamma receptor II-mediated antibody-dependent enhancement of dengue virus infection. J. Gen. Virol. 74:839-844.
155. Malinoski, F. J., S. E. Hasty, M. A. Ussery, and J. M. Dalrymple. 1990. Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. Antiviral Res. 13:139-149.
156. Marcellin, P., S. Levy, and S. Erlinger. 1997. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 26:133S-136S.
157. Marchevsky, R. S., J. Mariano, V. S. Ferreira, E. Almeida, M. J. Cerqueira, R. Carvalho, J. W. Pissurno, A. P. da Rosa, M. C. Simoes, C. N. Santos, et al. 1995. Phenotypic analysis of yellow fever virus derived from complementary DNA. Am. J. Trop. Med. Hyg. 52:75-80.
158. Martin, F., N. Dimasi, C. Volpari, C. Perrera, S. Di Marco, M. Brunetti, C. Steinkuhler, R. De Francesco, and M. Sollazzo. 1998. Design of selective eglin inhibitors of HCV NS3 proteinase. Biochemistry 37:11459-11468.
159. Martinot Peignoux, M., N. Boyer, M. Pouteau, C. Castelnau, N. Giuily, V. Duchatelle, A. Auperin, C. Degott, J. P. Benhamou, S. Erlinger, and P. Marcellin. 1998. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J. Hepatol. 29:214-223.
160. Marwick, C. 1998. First "antisense" drug will treat CMV retinitis. JAMA 280:871.
161. McCormick, J. B., I. J. King, P. A. Webb, C. L. Scribner, R. B. Craven, K. M. Johnson, L. H. Elliott, and R. Belmont Williams. 1986. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314:20-26.
162. McHutchison, J. G., S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M. H. Ling, S. Cort, and J. K. Albrecht. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
163. Meehan, J. T., H. D. Lehmkuhl, R. C. Cutlip, and S. R. Bolin. 1998. Acute pulmonary lesions in sheep experimentally infected with bovine viral diarrhoea virus. J. Comp. Pathol. 119:277-292.
164. Mendez, E., N. Ruggli, M. S. Collett, and C. M. Rice. 1998. Infectious bovine viral diarrhea virus (strain NADL) RNA from stable cDNA clones: a cellular insert determines NS3 production and viral cytopathogenicity. J. Virol. 72:4737-4745.
165. Meyers, G., and H. J. Thiel. 1996. Molecular characterization of pestiviruses. Adv. Virus Res. 47:53-118.
166. Misra, U. K., J. Kalita, and M. Srivastava. 1998. Prognosis of Japanese encephalitis: a multivariate analysis. J. Neurol. Sci. 161:143-147.
167. Monath, T. P. 1987. Yellow fever: a medically neglected disease. Report on a seminar. Rev. Infect. Dis. 9:165-175.
168. Monath, T. P., K. R. Brinker, F. W. Chandler, G. E. Kemp, and C. B. Cropp. 1981. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am. J. Trop. Med. Hyg. 30:431-443.
169. Monath, T. P., and F. X. Heinz. 1996. Flaviviruses, p. 961-1034. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 1. Lippincott-Raven Publishers, Philadelphia, Pa.
170. Moradpour, D., T. Wakita, J. R. Wands, and H. E. Blum. 1998. Tightly regulated expression of the entire hepatitis C virus structural region in continuous human cell lines. Biochem. Biophys. Res. Commun. 246:920-924.
171. Morens, D. M. 1994. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin. Infect. Dis. 19:500-512.
172. Mori, A., K. Yamada, J. Kimura, T. Koide, S. Yuasa, E. Yamada, and T. Miyamura. 1996. Enzymatic characterization of purified NS3 serine proteinase of hepatitis C virus expressed in Escherichia coli. FEBS Lett. 378: 37-42.
173. Moriya, K., H. Fujie, Y. Shintani, H. Yotsuyanagi, T. Tsutsumi, K. Ishibashi, Y. Matsuura, S. Kimura, T. Miyamura, and K. Koike. 1998. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4:1065-1067.
174. Mounir, S. 1998. Hepatitis C virus replication in the nude mouse model, general session II, presentation 4. In Symposium on Emerging Therapies for Chronic Viral Hepatitis.
175. Negro, F., E. Giostra, L. Rubbia Brandt, G. Mentha, G. Colucci, P. Morel, R. Quadri, L. Perrin, and A. Hadengue. 1998. IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation. J. Med. Virol. 56:224-229.
176. Nettleton, P. F., and G. Entrican. 1995. Ruminant pestiviruses. Br. Vet. J. 151:615-642.
177. Nettleton, P. F., J. A. Gilray, P. Russo, and E. Dlissi. 1998. Border disease of sheep and goats. Vet. Res. 29:327-340.
178. Neyts, J., A. Meerbach, P. McKenna, and E. De Clercq. 1996. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res. 30:125-132.
179. Neyts, J., R. Snoeck, D. Schols, J. Balzarini, J. D. Esko, A. Van Schepdael, and E. De Clercq. 1992. Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate. Virology 189:48-58.
180. Ohkawa, K., N. Yuki, Y. Kanazawa, K. Ueda, E. Mita, Y. Sasaki, A. Kasahara, and N. Hayashi. 1997. Cleavage of viral RNA and inhibition of viral translation by hepatitis C virus RNA-specific hammerhead ribozyme in vitro. J. Hepatol. 27:78-84.
181. Osella, A. R., M. A. Massa, S. Joekes, N. Blanch, M. R. Yacci, S. Centonze, and S. Sileoni. 1998. Hepatitis B and C virus sexual transmission among homosexual men. Am. J. Gastroenterol. 93:49-52.
182. Pastoret, P. P., and M. Lambot. 1995. Biologie de l'infection des bovins par le Pestivirus responsable de la maladie des muqueuses. Bull. Mem. Acad. R. Med. Belg. 150:244-250. (In French.)
183. Pauly, T., M. Konig, H. J. Thiel, and A. Saalmuller. 1998. Infection with classical swine fever virus: effects on phenotype and immune responsiveness of porcine T lymphocytes. J. Gen. Virol. 79:31-40.
184. Pawlotsky, J. M., G. Germanidis, A. U. Neumann, M. Pellerin, P. O. Frainais, and D. Dhumeaux. 1998. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations. J. Virol. 72:2795-2805.
185. Pickering, J. M., H. C. Thomas, and P. Karayiannis. 1997. Predicted secondary structure of the hepatitis G virus and GB virus-A 5′untranslated regions consistent with an internal ribosome entry site. J. Viral Hepat. 4:175-184.
186. Pileri, P., Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, R. Petracca, A. J. Weiner, M. Houghton, D. Rosa, G. Grandi, and S. Abrignani. 1998. Binding of hepatitis C virus to CD81. Science 282:938-941.
187. Pontisso, P., C. Belluco, R. Bertorelle, L. De Moliner, L. Chieco Bianchi, D. Nitti, M. Lise, and A. Alberti. 1998. Hepatitis C virus infection associated with human hepatocellular carcinoma: lack of correlation with p53 abnormalities in Caucasian patients. Cancer 83:1489-1494.
188. Poole, T. L., C. Wang, R. A. Popp, L. N. Potgieter, A. Siddiqui, and M. S. Collett. 1995. Pestivirus translation initiation occurs by internal ribosome entry. Virology 206:750-754.
189. Porter, D. J. 1998. Inhibition of the hepatitis C virus helicase-associated ATPase activity by the combination of ADP, NaF, MgC12, and poly(rU). Two ADP binding sites on the enzyme-nucleic acid complex. J. Biol. Chem. 273:7390-7396.
190. Poynard, T., P. Marcellin, S. S. Lee, C. Niederau, G. S. Minuk, G. Ideo, V. Bain, J. Heathcote, S. Zeuzem, C. Trepo, and J. Albrecht. 1998. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432.
191. Pryor, M. J., R. C. Gualano, B. Lin, A. D. Davidson, and P. J. Wright. 1998. Growth restriction of dengue virus type 2 by site-specific mutagenesis of virus-encoded glycoproteins. J. Gen. Virol. 79:2631-2639.
192. Quin, J. W. 1997. Interferon therapy for acute hepatitis C viral infection - a review by meta-analysis. Aust. N. Z. J. Med. 27:611-617.
193. Ramirez Ronda, C. H., and C. D. Garcia. 1994. Dengue in the Western Hemisphere. Infect. Dis. Clin. North Am. 8:107-128.
194. Resti, M., C. Azzari, F. Mannelli, M. Moriondo, E. Novembre, M. de Martino, and A. Vierucci. 1998. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-I. Tuscany Study Group on Hepatitis C Virus Infection. Br. Med. J. 317:437-441.
195. Rice, C. M. 1996. Flaviviridae: the viruses and their replication, p. 931-960. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 1. Lippincolt-Raven Publishers, Philadelphia, Pa.
196. Rijnbrand, R., T. van der Straaten, P. A. Van Rijn, W. J. Spaan, and P. J. Bredenbeek. 1997. Internal entry of ribosomes is directed by the 5′ non-coding region of classical swine fever virus and is dependent on the presence of an RNA pseudoknot upstream of the initiation codon. J. Virol. 71:451-457.
197. Rosen, H. R., D. R. Gretch, M. Oehlke, K. D. Flora, K. G. Benner, J. M. Rabkin, and C. L. Corless. 1998. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 65:1178-1182.
198. Rosenwirth, B., D. A. Oren, E. Arnold, Z. L. Kis, and H. J. Eggers. 1995. SDZ 35-682, a new picornavirus capsid-binding agent with potent antiviral activity. Antiviral Res. 26:65-82.
199. Rostaing, L., J. Izopet, F. Moussion, L. Alric, D. Verdier, H. T. That, M. Duffaut, D. Durand, J. Puel, and J. M. Suc. 1997. HCV RNA clearance after treatment with interferon-alpha in chronic hemodialysis patients with or without coinfection by HGV/HGBV-C. Nephrologie 18:281-286. (In French.)
200. Rümenapf, T., G. Unger, J. H. Strauss, and H.-J. Thiel. 1993. Processing of the envelope glycoproteins of pestiviruses. J. Virol. 67:3288-3294.
201. Ryman, K. D., H. Xie, T. N. Ledger, G. A. Campbell, and A. D. Barrett. 1997. Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Virology 230:376-380.
202. Sakamoto, N., C. H. Wu, and G. Y. Wu. 1996. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J. Clin. Investig. 98:2720-2728.
203. Sali, D. L., R. Ingram, M. Wendel, D Gupta, C. McNemar, A. Tsarbopoulos, J. W. Chen, Z. Hong, R. Chase, C. Risano, R. Zhang, N. Yao, A. D. Kwong, L. Ramanathan, H. V. Le, and P. C. Weber. 1998. Serine protease of hepatitis C virus expressed in insect cells as the NS3/4A complex. Biochemistry 37:3392-3401.
204. Schols, D., S. Struyf, J. Van Damme, J. A. Este, G. Henson, and E. De Clercq. 1997. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186:1383-1388.
205. Shimizu, Y. K., H. Igarashi, T. Kiyohara, M. Shapiro, D. C. Wong, R. H. Purcell, and H. Yoshikura. 1998. Infection of a chimpanzee with hepatitis C virus grown in cell culture. J. Gen. Virol. 79:1383-1386.
206. Shoji, I., T. Suzuki, S. Chieda, M. Sato, T. Harada, T. Chiba, Y. Matsuura, and T. Miyamura. 1995. Proteolytic activity of NS3 serine proteinase of hepatitis C virus efficiently expressed in Escherichia coil. Hepatology 22: 1648-1655.
207. Sizova, D. V., V. G. Kolupaeva, T. V. Pestova, I. N. Shatsky, and C. U. Hellen. 1998. Specific interaction of eukaryotic translation initiation factor 3 with the 5′ nontranslated regions of hepatitis C virus and classical swine fever virus RNAs. J. Virol. 72:4775-4782.
208. Spector, F. C., L. Liang, H. Giordano, M. Sivaraja, and M. G. Peterson. 1998. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J. Virol. 72:6979-6987.
209. Steinkuhler, C., G. Biasiol, M. Brunetti, A. Urbani, U. Koch, R. Cortese, A. Pessi, and R. De Francesco. 1998. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 37:8899-8905.
210. Reference deleted.
211. Stephen, E. L., M. L. Sammons, W. L. Pannier, S. Baron, R. O. Spertzel, and H. B. Levy. 1977. Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J. Infect. Dis. 136:122-126.
212. Sudo, K., H. Inoue, Y. Shimizu, K. Yamaji, K. Konno, S. Shigeta, T. Kaneko, T. Yokota, and K. Shimotohno. 1996. Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography. Antiviral Res. 32:9-18.
213. Sudo, K., Y. Matsumoto, M. Matsushima, M. Fujiwara, K. Konno, K. Shimotohno, S. Shigeta, and T. Yokota. 1997. Novel hepatitis C virus protease inhibitors: thiazolidine derivatives. Biochem. Biophys. Res. Commun. 238:643-647.
214. Sumarmo, S. P., W. Talogo, A. Asrin, B. Isnuhandojo, and A. Sahudi. 1982. Failure of hydrocortisone to affect outcome in dengue shock syndrome. Pediatrics 69:45-49.
215. Summerfleld, A., S. M. Knotig, and K. C. McCullough. 1998. Lymphocyte apoptosis during classical swine fever: implication of activation-induced cell death. J. Virol. 72:1853-1861.
216. Taber, L. H., V. Knight, B. E. Gilbert, H. W. McClung, S. Z. Wilson, H. J. Norton, J. M. Thurson, W. H. Gordon, R. L. Atmar, and W. R. Schlaudt. 1983. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 72:613-618.
217. Takegami, T., E. Simamura, K. Hirai, and J. Koyama. 1998. Inhibitory effect of furanonaphthoquinone derivatives on the replication of Japanese encephalitis virus. Antiviral Res. 37:37-45.
218. Taliani, M., E. Bianchi, F. Narjes, M. Fossatelli, A. Urbani, C. Steinkuhler, R. De Francesco, and A. Pessi. 1996. A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. Anal. Biochem. 240:60-67.
219. Tan, B. H., J. Fu, R. J. Sugrue, E. H. Yap, Y. C. Chan, and Y. H. Tan. 1996. Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology 216:317-325.
220. Taremi, S. S., B. Beyer, M. Maher, N. Yao, W. Prosise, P. C. Weber, and B. A. Malcolm. 1998. Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Sci. 7:2143-2149.
221. Tassniyom, S., S. Vasanawathana, A. Chirawatkul, and S. Rojanasuphot. 1993. Failure of high-dose methylprednisolone in established dengue shock syndrome: a placebo-controlled, double-blind study. Pediatrics 92:111-115.
222. Tassniyom, S., S. Vasanawathana, T. Dhiensiri, A. Nisalak, and A. Chirawatkul. 1997. Failure of carbazochrome sodium sulfonate (AC-17) to prevent dengue vascular permeability or shock: a randomized, controlled trial. J. Pediatr. 131:525-528.
223. Tautz, N., G. Meyers, R. Stark, E. J. Dubovi, and H.-J. Thiel. 1996. Cytopathogenicity of a pestivirus correlates with a 27-nucleotide insertion. J. Virol. 70:7851-7858.
224. Tautz, N., G. Meyers, and H.-J. Thiel. 1998. Pathogenesis of mucosal disease, a deadly disease of cattle caused by a pestivirus. Clin. Diagn. Virol. 10:121-127.
225. Taylor, J. L., C. Schoenherr, and S. E. Grossberg. 1980. Protection against Japanese encephalitis virus in mice and hamsters by treatment with carboxymethylacridanone, a potent interferon inducer. J. Infect. Dis. 142:394-399.
226. Terpstra, C., and G. Wensvoort. 1997. A congenital persistent infection of bovine virus diarrhoea virus in pigs: clinical, virological and immunological observations. Vet. Q. 19:97-101.
227. Thiel, H.-J., P. G. W. Plagemann, and V. Moennig. 1996. Pestiviruses, p. 1059-1073. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 1. Lippincott-Raven Publishers. Philadelphia, Pa.
228. Thomas, S. L., M. L. Newell, C. S. Peckham, A. E. Ades, and A. J. Hall. 1998. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int. J. Epidemiol. 27:108-117.
229. Tomei, L., C. Failla, R. L. Vitale, E. Bianchi, and R. De Francesco. 1996. A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activation of the NS3 protease. J. Gen. Virol. 77:1065-1070.
230. Tong, M. J., L. M. Blatt, L. T. Tong, K. Sayadzadeh, and A. Conrad. 1998. Long-term retreatment in chronic hepatitis C patients who were non-responders to an initial course of interferon-alpha 2b. J. Viral Hepat. 5:323-331.
231. Tsai, T. F., F. Popovici, C. Cernescu, G. L. Campbell, and N. I. Nedelcu. 1998. West Nile encephalitis epidemic in southeastern Romania. Lancet 352:767-771.
232. Tsukiyama, K. K., N. lizuka, M. Kohara, and A. Nomoto. 1992. Internal ribosome entry site within hepatitis C virus RNA. J. Virol. 66:1476-1483.
233. Urbani, A., R. Bazzo, M. C. Nardi, D. O. Cicero, R. De Francesco, C. Steinkuhler, and G. Barbato. 1998. The metal binding site of the hepatitis C virus NS3 protease. A spectroscopic investigation. J. Biol. Chem. 273: 18760-18769.
234. Valle, R. P., and B. Falgout. 1998. Mutagenesis of the NS3 protease of dengue virus type 2. J. Virol. 72:624-632.
235. Van Campen, H., E. S. Williams, J. Edwards, W. Cook, and G. Stout. 1997. Experimental infection of deer with bovine viral diarrhea virus. J. Wildl. Dis. 33:567-573.
236. van Olphen, A. L., and R. O. Donis. 1997. Identification of bovine viral diarrhea virus nonstructural polypeptide NS4B/P38. Virus Res. 51:197-201.
237. Venugopal, K., and E. A. Gould. 1994. Towards a new generation of flavivirus vaccines. Vaccine 12:966-975.
238. Vilcek, S., T. Stadejek, P. A. Ballagi, J. P. Lowings, D. J. Paton, and S. Belak. 1996. Genetic variability of classical swine fever virus. Virus Res. 43:137-147.
239. Vishnuvardhan, D., N. Kakiuchi, P. T. Urvil, K. Shimotohno, P. K. Kumar, and S. Nishikawa. 1997. Expression of highly active recombinant NS3 protease domain of hepatitis C virus in E. coli. FEBS Lett. 402:209-212.
240. Wakita, T., D. Moradpour, K. Tokushihge, and J. R. Wands. 1999. Antiviral effects of antisense RNA on hepatitis C virus RNA translation and expression. J. Med. Virol. 57:217-222.
241. Walker, M. A. 1999. Hepatitis C virus: an overview of current approaches and progress. Drug Discov. Today 4:518-529.
242. Weissenbock, H., A. Suchy, and H. Holzmann. 1998. Tick-borne encephalitis in dogs: neuropathological findings and distribution of antigen. Acta Neuropathol. Berl. 95:361-366.
243. Welch, P. J., R. Tritz, S. Yei, M. Leavitt, M. Yu, and J. Barber. 1996. A potential therapeutic application of hairpin ribozymes: in vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther. 3:994-1001.
244. Wengler, G., and G. Wengler. 1989. Cell-associated West Nile flavivirus is covered with E+pre-M protein heterodimers which are destroyed and reorganized by proteolytic cleavage during virus release. J. Virol. 63:2521-2526.
245. Wengler, G., and G. Wengler. 1993. The NS 3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity. Virology 197:265-273.
246. Westaway, E. G. 1987. Flavivirus replication strategy. Adv. Virus Res. 33:45-90.
247. Wilkinson, T. C., P. R. Bunyard, K. Quirk, and C. S. Wilkinson. 1997. Characterisation of an HCV NS3/NS4A proteinase fusion protein expressed in E. coli using synthetic peptide substrates. Biochem. Soc. Trans. 25:S624.
248. Wiskerchen, M., S. K. Belzer, and M. S. Collett. 1991. Pestivirus gene expression: the first protein product of the bovine viral diarrhea virus large open reading frame, p20, possesses proteolytic activity. J. Virol. 65:4508-4514.
249. World Health Organization. 1993. Monograph on dengue/dengue hemorrhagic fever. Regional publication, SEARO no. 22. World Health Organization, Geneva, Switzerland.
250. World Health Organization. 1997. Dengue bulletin. Bull. W. H. O. 21:1-15.
251. Wu, S. J., C. G. Hayes, D. R. Dubois, M. G. Windheuser, Y. H. Kang, D. M. Watts, and D. G. Sieckmann. 1995. Evaluation of the severe combined immunodeficient (SCID) mouse as an animal model for dengue viral infection. Am. J. Trop. Med. Hyg. 52:468-476.
252. Xu, J., E. Mendez, P. R. Caron, C. Lin, M. A. Murcko, M. S. Collett, and C. M. Rice. 1997. Bovine viral diarrhea virus NS3 serine proteinase: polyprotein cleavage sites, cofactor requirements, and molecular model of an enzyme essential for pestivirus replication. J. Virol. 71:5312-5322.
253. Yamada Osaki, M., R. Sumazaki, Y. Kajiwara, T. Miyakawa, A. Shirahata, and A. Matsui. 1998. Natural course of HGV infection in haemophiliacs. Br. J. Haematol. 102:616-621.
254. Yamada, K., A. Mori, M. Seki, J. Kimura, S. Yuasa, Y. Matsuura, and T. Miyamura. 1998. Critical point mutations for hepatitis C virus NS3 proteinase. Virology 246:104-112.
255. Yamashita, T., S. Kaneko, Y. Shirota, W. Qin, T. Nomura, K. Kobayashi. and S. Murakami. 1998. RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. J. Biol. Chem. 273:15479-15486.
256. Yan, Y., Y. Li, S. Munshi, V. Sardana, J. L. Cole, M. Sardana, C. Steinkuehler, L. Tomei, R. De Francesco, L. C. Kuo, and Z. Chen. 1998. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci. 7:837-847.
257. Yang, G., F. X. Caroli Bosc, C. Laffont, D. Bianchi, S. Dantin, J. C. Lefebvre, and A. Doglio. 1998. Hepatitis G and C viruses respond to interferon-alpha with different virologie kinetics. Dig. Dis. Sci. 43:1307-1310.
258. Yao, N., T. Hesson, M. Cable, Z. Hong, A. D. Kwong, H. V. Le, and P. C. Weber. 1997. Structure of the hepatitis C virus RNA helicase domain. Nat. Struct. Biol. 4:463-467.
259. Yuan, Z. H., U. Kumar, H. C. Thomas, Y. M. Wen, and J. Monjardino. 1997. Expression, purification, and partial characterization of HCV RNA polymerase. Biochem. Biophys. Res. Commun. 232:231-235.
260. Zeuzem, S., G. Teuber, J. H. Lee, B. Ruster, and W. K. Roth. 1996. Risk factors for the transmission of hepatitis C. J. Hepatol. 24:3-10.
261. Zhao, W. D., E. Wimmer, and F. C. Lahser. 1999. Poliovirus/Hepatitis C virus (internal ribosomal entry site-core) chimeric viruses: improved growth properties through modification of a proteolytic cleavage site and requirement for core RNA sequences but not for core-related polypeptides. J. Virol. 73:1546-1554.
262. Zhong, W., L. L. Gutshall, and A. M. Del Vecchio. 1998. Identification and characterization of an RNA-dependent RNA polymerase activity within the nonstructural protein 5B region of bovine viral diarrhea virus. J. Virol. 72:9365-9369.
263. Zoulim, F., J. Haem, S. S. Ahmed, P. Chossegros, F. Habersetzer, M. Chevallier, F. Bailly, and C. Trepo. 1998. Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J. Viral Hepat. 5:193-198.